Return of Results (ROR) Limited Duration Working Group initiated in late 2022

The ROR LDWG led by Nicole Hartmann (Novartis) will be leading a workshop session at the F2F Meeting which will define the scope and plans for the group in 2023. The ROR LDWG has representation from the following companies: Abbvie, Amge, AstraZeneca, Biogen, BioMarin, BMS, Debiopharm, Ionis, Merck, Novartis, Pfizer, Regeneron & Roche.

March Monthly Meeting Speaker
F2F Meeting Summary